SEARCH:   Advanced

Blood, 1 January 2008, Vol. 111, No. 1, pp. 109-111. Prepublished online as a Blood First Edition Paper on October 15, 2007; DOI 10.1182/blood-2007-03-078725. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2007-03-078725v1 111/1/109    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Schulz, H. Articles by Reiser, M. Search for Related Content PubMed PubMed Citation Articles by Schulz, H. Articles by Reiser, M. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 23, 2007 Accepted September 23, 2007 Rituximab in relapsed lymphocyte-predominant Hodgkin Lymphoma: Long-term results of a phase-II trial of the German Hodgkin Lymphoma Study Group (GHSG) Holger Schulz, Ute Rehwald, Franck Morschhauser, Thomas Elter, Christoph Driessen, Thomas Rudiger, Peter Borchmann, Roland Schnell, Volker Diehl, Andreas Engert, and Marcel Reiser* Department I of Internal Medicine, University of Cologne, Cologne, Germany Hospitalier de Universitaire Lille, Lille, France Medizinische Klinik und Poliklinik II, Universitatsklinikum Tubingen, Tubingen, Germany Department of Pathology, University Wurzburg, Wurzburg, Germany * Corresponding author; email: marcel.reiser{at}uni-koeln.de. Since nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) express CD20, rituximab may be used as a non-mutagenic treatment option to avoid late toxicities in this rather indolent entity. Between 1999-2004 the German Hodgkin Study Group investigated the activity of rituximab (375mg/m2 x 4) in a phase-II trial in 21 relapsed or refractory NLPHL patients. The initial diagnosis of NLPHL was confirmed in 15/21 enrolled patients by reference pathology. The remaining cases were reclassified as Hodgkin lymphoma transformed to T-cell rich B-cell lymphoma (TCRBCL) (n=2) or CD20+ classical Hodgkin lymphoma (cHL) (n=4). In NLPHL patients the overall response rate was 94%, including 8 CR and 6 PR. With a median follow-up of 63 months (range 3-84), the median time to progression was 33 months, with the median OS not reached. Thus, rituximab is highly effective in relapsed and refractory NLPHL. This study is registered at http://www.klinisches-studienzentrum.de/trial/285. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. I. Lee and A. S. LaCasce Nodular Lymphocyte Predominant Hodgkin Lymphoma Oncologist, July 1, 2009; 14(7): 739 - 751. [Abstract] [Full Text] [PDF] A. Engert, D. A. Eichenauer, M. Dreyling, and On behalf of the ESMO Guidelines Working Group Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv108 - iv109. [Full Text] [PDF] M. Crump Management of Hodgkin Lymphoma in Relapse after Autologous Stem Cell Transplant Hematology, January 1, 2008; 2008(1): 326 - 333. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020